Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses AZTA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AZTA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| John Marotta | $900,000 | $0 | $8,386,297 | $0 | $1,063,656 | $0 | $21,462 | $10,371,414 |
| President and Chief Executive Officer | ||||||||
| Lawrence Lin | 463,154 | 250,000 | 2,784,716 | 0 | 398,090 | 0 | 13,792 | 3,909,752 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Ephraim Starr | 191,077 | 0 | 2,142,271 | 0 | 143,705 | 0 | 5,187 | 2,482,240 |
| Senior Vice President, General Counsel and Corporate Secretary | ||||||||
| Jason Joseph | 355,615 | 0 | 1,388,088 | 0 | 321,246 | 0 | 205,753 | 2,270,703 |
| Former Senior Vice President, General Counsel and Corporate Secretary | ||||||||
| Olga Pirogova | 391,692 | 0 | 1,041,091 | 0 | 252,501 | 0 | 16,501 | 1,701,786 |
| Senior Vice President and Chief Human Resources Officer | ||||||||
| Ginger Zhou | 410,123 | 0 | 867,593 | 0 | 261,429 | 0 | 9,228 | 1,548,373 |
| Senior Vice President, President GENEWIZ | ||||||||
| Herman Cueto | 100,000 | 240,000 | 0 | 0 | 0 | 0 | 430,000 | 770,000 |
| Former Executive Vice President and Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| John Marotta | $10,371,414 | $638,811 | — | +9,732,603 |
| Lawrence Lin | 3,909,752 | — | — | — |
| Ephraim Starr | 2,482,240 | — | — | — |
| Jason Joseph | 2,270,703 | 2,408,144 | 1,444,170 | −137,441 |
| Olga Pirogova | 1,701,786 | — | — | — |
| Ginger Zhou | 1,548,373 | 1,573,935 | 849,019 | −25,562 |
| Herman Cueto | 770,000 | 3,566,008 | — | −2,796,008 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Robyn C. Davis | Director | 2026-02-05 | A | 5,663 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martin Madaus | Director | 2026-02-05 | A | 5,663 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dipal Doshi | Director | 2026-02-05 | A | 5,663 | 28 | 157,715 | Common | Form 4 ↗ |
| Tina S. Nova | Director | 2026-02-05 | A | 5,663 | 28 | 157,715 | Common | Form 4 ↗ |
| William L. Cornog | Director | 2026-02-05 | A | 5,663 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Erica J. McLaughlin | Director | 2026-02-05 | A | 5,663 | 28 | 157,715 | Common | Form 4 ↗ |
| Frank E. Casal | Director | 2026-02-05 | A | 7,243 | 28 | 201,718 | Common | Form 4 ↗ |
| Quentin G. Koffey | Director | 2026-02-05 | A | 5,663 | 0 | 0 | Common | Form 4 ↗ |
| William E. Martin III | President Multiomics | 2026-04-28 | A | 17,790 | 24 | 431,230 | Common | Form 4 ↗ |
| Ephraim Starr | SVP, Gen Counsel & Secretary | 2026-05-15 | D | 3,621 | 16 | 58,008 | Common | Form 4 ↗ |
| William L. Cornog | Director | 2026-05-18 | A | 10,000 | 16 | 163,800 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| John Marotta | PSU | 2024-11-15 | 41,811 | 83,622 | — | 167,244 | $4,915,147 |
| Lawrence Lin | RSU | 2024-12-05 | — | — | 23,045 | — | 1,037,025 |
| Ginger Zhou | PSU | 2024-11-15 | 4,326 | 8,651 | — | 17,302 | 508,490 |
| Jason Joseph | PSU | 2024-11-15 | 6,921 | 13,841 | — | 27,682 | 813,549 |
| Jason Joseph | RSU | 2024-11-15 | — | — | 13,841 | — | 574,540 |
| Ginger Zhou | RSU | 2024-11-15 | — | — | 8,651 | — | 359,103 |
| John Marotta | RSU | 2024-11-15 | — | — | 83,622 | — | 3,471,149 |
| Olga Pirogova | PSU | 2024-11-15 | 5,191 | 10,381 | — | 20,762 | 610,176 |
| Ephraim Starr | RSU | 2025-05-15 | — | — | 37,779 | — | 1,009,077 |
| Ephraim Starr | PSU | 2025-05-15 | 18,890 | 37,779 | — | 75,558 | 1,133,194 |
| Lawrence Lin | PSU | 2024-12-05 | 11,523 | 23,045 | — | 46,090 | 1,488,131 |
| Lawrence Lin | RSU | 2024-12-05 | — | — | 5,768 | — | 259,560 |
| Olga Pirogova | RSU | 2024-11-15 | — | — | 10,831 | — | 430,915 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| John Marotta | $3,471,149 | $4,915,147 | $0 | 58.6% |
| Lawrence Lin | 1,296,585 | 1,488,131 | 0 | 53.4% |
| Ginger Zhou | 359,103 | 508,490 | 0 | 58.6% |
| Jason Joseph | 574,540 | 813,549 | 0 | 58.6% |
| Olga Pirogova | 430,915 | 610,176 | 0 | 58.6% |
| Ephraim Starr | 1,009,077 | 1,133,194 | 0 | 52.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Lawrence Lin | PSU | 23,045 | — | $949,684 |
| John Marotta | PSU | 83,622 | — | 3,400,907 |
| Olga Pirogova | RSU | 1,069 | — | 30,702 |
| Lawrence Lin | RSU | 28,813 | — | 827,509 |
| Jason Joseph | PSU | 16,493 | — | 473,679 |
| Jason Joseph | PSU | 11,331 | — | 325,426 |
| John Marotta | PSU | 9,819 | — | 282,002 |
| Jason Joseph | RSU | 3,665 | — | 105,259 |
| John Marotta | RSU | 2,182 | — | 62,667 |
| Olga Pirogova | PSU | 9,621 | — | 276,315 |
| Ginger Zhou | PSU | 5,666 | — | 162,728 |
| Olga Pirogova | RSU | 3,166 | — | 90,928 |
| Ginger Zhou | RSU | 3,166 | — | 90,928 |
| Ginger Zhou | RSU | 1,069 | — | 30,702 |
| Ginger Zhou | RSU | 629 | — | 18,065 |
| Jason Joseph | RSU | 1,259 | — | 36,158 |
| Ephraim Starr | PSU | 37,779 | — | 1,218,373 |
| John Marotta | RSU | 83,622 | — | 2,401,624 |
| Ephraim Starr | RSU | 37,779 | — | 1,085,013 |
| Olga Pirogova | PSU | 10,381 | — | 422,195 |
| Olga Pirogova | RSU | 10,381 | — | 298,142 |
| Ginger Zhou | RSU | 8,651 | — | 248,457 |
| Jason Joseph | PSU | 13,841 | — | 562,913 |
| Jason Joseph | RSU | 13,841 | — | 397,514 |
| Ginger Zhou | PSU | 8,651 | — | 351,836 |
| Ginger Zhou | PSU | 9,621 | — | 276,315 |
Our executive compensation program is intended to reward our senior leadership team for achieving performance that is directly tied to our annual operating and longer-term strategic plans which are designed to create value for our shareholders. We believe that our plan structure clearly aligns our reward outcomes with the interests of our shareholders, as reinforced by our dialogue with shareholders over the last several years.
| CEO STI target (% of salary) | 110% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-01-28 | 38,413,005 | 1,479,264 | 37,724 | 96.29% | Passed |
| 2025 | 2025-01-30 | 40,649,757 | 228,004 | 511,173 | 99.44% | Passed |
| 2024 | 2024-01-30 | 49,109,585 | 900,374 | 123,893 | 98.2% | Passed |
| 2023 | 2023-01-31 | 59,630,140 | 756,469 | 35,855 | 98.75% | Passed |
| 2022 | 2022-01-24 | 65,645,925 | 440,161 | 121,150 | 99.33% | Passed |
| 2021 | 2021-01-26 | 66,268,061 | 254,028 | 39,450 | 99.62% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-01-28 | 96.29%a |
| 2025 | 2025-01-30 | 99.44%b |
| 2024 | 2024-01-30 | 98.2%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not have any effect on the results of those deliberations.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not have any effect on the results of those deliberations.”.
c. Approved under the standard stated in the filing — “Abstentions will have no effect on the results of the vote on Proposal No.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 178.8 : 1 |
|---|---|
| CEO total compensation | $10,371,414 |
| Median employee compensation | $57,992 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Frank E. CasalIndependent · Board Chair · Audit (Chair) · Nominating and Governance | $134,375 | $270,390 | $0 | $0 | $0 | $404,765 |
| Robyn C. DavisIndependent · Human Resources and Compensation (Chair) · Nominating and Governance | 91,814 | 211,373 | 0 | 0 | 0 | 303,187 |
| Erica J. McLaughlinIndependent · Environmental, Social and Governance (Chair) · Audit | 90,000 | 211,373 | 0 | 0 | 0 | 301,373 |
| Martin MadausIndependent · Nominating and Governance (Chair) · Value Creation | 83,750 | 211,373 | 0 | 0 | 0 | 295,123 |
| Tina S. NovaIndependent · Environmental, Social and Governance · Human Resources and Compensation | 81,875 | 211,373 | 0 | 0 | 0 | 293,248 |
| Quentin G. KoffeyIndependent · Human Resources and Compensation · Value Creation · Newly elected | 78,125 | 211,373 | 0 | 0 | 0 | 289,498 |
| William L. CornogIndependent · Value Creation (Chair) · Newly elected | 77,500 | 211,373 | 0 | 0 | 0 | 288,873 |
| Alan J. MalusIndependent · Value Creation · Newly elected | 75,625 | 211,373 | 0 | 0 | 0 | 286,998 |
| Dipal DoshiIndependent · Audit | 56,250 | 211,373 | 0 | 0 | 0 | 267,623 |
| John P. MarottaEmployee director · Value Creation | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | $215,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 50,000 / 50,000 / 50,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $769,314 |
| Equity awards (grant-date value) | $1,961,374 |
| All other compensation | $0 |
| Total cost of the board | $2,730,688 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Azenta, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Azenta, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Natera, Inc. | 2025 | Steven Chapman | $853,710 | $12,979,558 | $0 | $1,114,151 | $14,957,319 |
| 2 | Twist Bioscience Corporation | 2025 | Emily Leproust | 720,000 | 11,998,134 | 0 | 932,918 | 13,781,570 |
| 3 | Haemonetics Corporation | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 4 | Medpace Holdings, Inc. | 2025 | August Troendle | 937,417 | 0 | 9,999,999 | 0 | 11,443,766 |
| 5 | Sotera Health Company | 2025 | Michael Petras | 1,130,699 | 8,022,400 | 0 | 1,484,890 | 10,656,063 |
| 6 | Azenta, Inc. | 2025 | John Marotta | 900,000 | 8,386,297 | 0 | 1,063,656 | 10,371,414 |
| 7 | Maravai LifeSciences Holdings Inc. | 2025 | Bernd Brust | 388,863 | 7,660,000 | 1,460,000 | 425,343 | 10,129,708 |
| 8 | NeoGenomics, Inc. | 2025 | Tony Zook | 601,539 | 3,999,997 | 3,998,235 | 513,400 | 9,127,092 |
| 9 | Guardant Health, Inc. | 2025 | AmirAli Talasaz | 1 | 8,647,709 | 0 | 0 | 8,661,227 |
| 10 | Bio-Techne Corporation | 2025 | Kim Kelderman | 936,000 | 3,929,942 | 1,932,848 | 1,318,917 | 8,151,181 |
| 11 | Tandem Diabetes Care, Inc. | 2025 | John Sheridan | 790,583 | 5,367,796 | 0 | 674,090 | 6,858,503 |
| 12 | Certara, Inc. | 2025 | William Feehery | 795,675 | 4,927,502 | 0 | 747,935 | 6,491,387 |
| 13 | 10x Genomics, Inc. | 2025 | Serge Saxonov | 674,250 | 5,020,269 | 0 | 634,725 | 6,329,244 |
| 14 | Repligen Corporation | 2025 | Olivier Loeillot | 860,000 | 3,374,853 | 1,095,626 | 774,000 | 6,114,771 |
| 15 | Myriad Genetics, Inc. | 2025 | Samraat Raha | 856,901 | 3,989,729 | 0 | 814,660 | 5,686,740 |
| 16 | Cryoport, Inc. | 2025 | Jerrell Shelton | 967,845 | 192,300 | 306,869 | 908,510 | 2,375,524 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Azenta, Inc. | 107.4% | PSU 50 · RSU 50 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
| 10x Genomics, Inc. | 93% | PSU 60 · RSU 40 | Yes — 3-year Relative TSR | Alpine Rewards LLC |
| Bio-Techne Corporation | 128.1% | PSU 50 · Options 25 · RSU 25 | No | Aon Talent |
| Certara, Inc. | 94% | PSU 60 · RSU 40 | Yes — annualized total stockholder return (ATSR) | Meridian Compensation Partners |
| Cryoport, Inc. | 92.2% | Options 62 · RSU 38 | not disclosed | Frederic W. Cook & Co., Inc. |
| Guardant Health, Inc. | 140% | PSU 50 · RSU 50 | No | Aon |
| Haemonetics Corporation | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| Maravai LifeSciences Holdings Inc. | not disclosed | not disclosed | No | Meridian Compensation Partners, LLC |
| Medpace Holdings, Inc. | 52.5% | Options 100 | not disclosed | Total Compensation Solutions (TCS) |
| Myriad Genetics, Inc. | 89% | RSU 50 · PSU 50 | Yes | Mercer |
| Natera, Inc. | 131.1% | PSU 50 · RSU 50 | No | Aon |
| NeoGenomics, Inc. | 60% | RSU 50 · Options 50 | not disclosed | WTW |
| Repligen Corporation | 100% | RSU 50 · PSU 25 · Options 25 | No | Meridian Compensation Partners, LLC |
| Sotera Health Company | 103% | PSU 40 · RSU 40 · Other 20 | No | Exequity |
| Tandem Diabetes Care, Inc. | 87% | PSU 50 · RSU 50 | Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027 | WTW |
| Twist Bioscience Corporation | 129.6% | PSU 50 · RSU 50 | No | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, John Marotta | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Summary Compensation Table” · page 44. As printed: 10,371,414. Filing ↗machine: r2 · c22 · span 1247118–1247129 |
| 2 | Section 01, Lawrence Lin | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Summary Compensation Table” · page 44. As printed: 3,909,752. Filing ↗machine: r5 · c22 · span 1259116–1259125 |
| 3 | Section 01, Ephraim Starr | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Summary Compensation Table” · page 44. As printed: 2,482,240. Filing ↗machine: r11 · c22 · span 1283000–1283009 |
| 4 | Section 01, Jason Joseph | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Summary Compensation Table” · page 44. As printed: 2,270,703. Filing ↗machine: r14 · c22 · span 1294848–1294857 |
| 5 | Section 01, Olga Pirogova | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Summary Compensation Table” · page 44. As printed: 1,701,786. Filing ↗machine: r17 · c22 · span 1307329–1307338 |
| 6 | Section 01, Ginger Zhou | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Summary Compensation Table” · page 44. As printed: 1,548,373. Filing ↗machine: r20 · c22 · span 1319485–1319494 |
| 7 | Section 01, Herman Cueto | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Summary Compensation Table” · page 44. As printed: 770,000. Filing ↗machine: r8 · c22 · span 1270955–1270962 |
| 8 | Section 03, John Marotta PSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r4 · c22 · span 1358630–1358636 |
| 9 | Section 03, Lawrence Lin RSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r7 · c22 · span 1372110–1372116 |
| 10 | Section 03, Ginger Zhou PSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r20 · c22 · span 1431785–1431790 |
| 11 | Section 03, Jason Joseph PSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r14 · c22 · span 1404028–1404034 |
| 12 | Section 03, Jason Joseph RSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r14 · c22 · span 1404028–1404034 |
| 13 | Section 03, Ginger Zhou RSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r20 · c22 · span 1431785–1431790 |
| 14 | Section 03, John Marotta RSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r4 · c22 · span 1358630–1358636 |
| 15 | Section 03, Olga Pirogova PSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r18 · c16 · span 1422053–1422059 |
| 16 | Section 03, Ephraim Starr RSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r11 · c22 · span 1390503–1390509 |
| 17 | Section 03, Ephraim Starr PSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r11 · c22 · span 1390503–1390509 |
| 18 | Section 03, Lawrence Lin PSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r7 · c22 · span 1372110–1372116 |
| 19 | Section 03, Lawrence Lin RSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r8 · c22 · span 1376378–1376383 |
| 20 | Section 03, Olga Pirogova RSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r17 · c22 · span 1418146–1418152 |
| 21 | Section 07, pay ratio | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “CEO Pay Ratio”. As printed: 178.8 : 1. Filing ↗ |
| 22 | Section 08, Frank E. Casal | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Director Compensation”. As printed: 404,765. Filing ↗machine: t90 · r2 · c10 · span 653547–653554 |
| 23 | Section 08, Robyn C. Davis | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Director Compensation”. As printed: 303,187. Filing ↗machine: t90 · r4 · c10 · span 657673–657680 |
| 24 | Section 08, Erica J. McLaughlin | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Director Compensation”. As printed: 301,373. Filing ↗machine: t90 · r9 · c10 · span 667846–667853 |
| 25 | Section 08, Martin Madaus | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Director Compensation”. As printed: 295,123. Filing ↗machine: t90 · r7 · c10 · span 663719–663726 |
| 26 | Section 08, Tina S. Nova | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Director Compensation”. As printed: 293,248. Filing ↗machine: r10 · c10 · span 669948–669955 |
| 27 | Section 08, Quentin G. Koffey | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Director Compensation”. As printed: 289,498. Filing ↗machine: r6 · c10 · span 661782–661789 |
| 28 | Section 08, William L. Cornog | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Director Compensation”. As printed: 288,873. Filing ↗machine: r3 · c10 · span 655482–655489 |
| 29 | Section 08, Alan J. Malus | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Director Compensation”. As printed: 286,998. Filing ↗machine: r8 · c10 · span 665920–665927 |
| 30 | Section 08, Dipal Doshi | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Director Compensation”. As printed: 267,623. Filing ↗machine: t90 · r5 · c10 · span 659591–659598 |
| 31 | Section 08, John P. Marotta | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 32 | Section 02, Robyn C. Davis 2026-02-05 | Form 4 | 2026-02-06 | 0001193125-26-041473 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Martin Madaus 2026-02-05 | Form 4 | 2026-02-06 | 0001193125-26-041485 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Dipal Doshi 2026-02-05 | Form 4 | 2026-02-06 | 0001193125-26-041482 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Tina S. Nova 2026-02-05 | Form 4 | 2026-02-06 | 0001193125-26-041527 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, William L. Cornog 2026-02-05 | Form 4 | 2026-02-06 | 0001193125-26-041487 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Erica J. McLaughlin 2026-02-05 | Form 4 | 2026-02-06 | 0001193125-26-041476 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Frank E. Casal 2026-02-05 | Form 4 | 2026-02-06 | 0001193125-26-041478 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Quentin G. Koffey 2026-02-05 | Form 4 | 2026-05-12 | 0001104659-26-059359 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, William E. Martin III 2026-04-28 | Form 4 | 2026-04-30 | 0001949513-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Ephraim Starr 2026-05-15 | Form 4 | 2026-05-18 | 0002069816-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, William L. Cornog 2026-05-18 | Form 4 | 2026-05-19 | 0001193125-26-230764 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 06, 2026 vote | Form 8-K | 2026-01-29 | 0001437749-26-002409 | Item 5.07 · say-on-pay result. As reported: 96.29% (votes for as printed: 38,413,005). Filing ↗ |
| 44 | Section 06, 2025 vote | Form 8-K | 2025-02-05 | 0001437749-25-002824 | Item 5.07 · say-on-pay result. As reported: 99.44% (votes for as printed: 40,649,757). Filing ↗ |
| 45 | Section 06, 2024 vote | Form 8-K | 2024-02-01 | 0001558370-24-000691 | Item 5.07 · say-on-pay result. As reported: 98.2% (votes for as printed: 49,109,585). Filing ↗ |
| 46 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 47 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 48 | Section 09b board cost (computed) | Computed | — | computed | Cash 769,314 + equity 1,961,374 + all other 0 = 2,730,688, summed across the director compensation table rows.machine: formula: Σ = 2,730,688 |
| 49 | Natera, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047770 | CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878 |
| 50 | Twist Bioscience Corporation, Section 10b CEO total | DEF 14A | 2026-01-06 | 0001581280-26-000006 | CEO total compensation as printed in Twist Bioscience Corporation's own proxy. As printed: 13,781,570. Filing ↗machine: t34 · r2 · c15 · span 1510951–1510961 |
| 51 | Haemonetics Corporation, Section 10b CEO total | DEF 14A | 2026-06-09 | 0000313143-26-000074 | CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. Filing ↗machine: span 718173–718183 |
| 52 | Medpace Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001668397-26-000012 | CEO total compensation as printed in Medpace Holdings, Inc.'s own proxy. As printed: 11,443,766. Filing ↗machine: t43 · r3 · c9 · span 495770–495781 |
| 53 | Sotera Health Company, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001104659-26-040937 | CEO total compensation as printed in Sotera Health Company's own proxy. As printed: 10,656,063. Filing ↗machine: span 996859–996869 |
| 54 | Azenta, Inc. (subject), Section 10b CEO total | DEF 14A | 2025-12-18 | 0001140361-25-046064 | CEO total compensation as printed in Azenta, Inc.'s own proxy. As printed: 10,371,414. Filing ↗machine: r2 · c22 · span 1247118–1247129 |
| 55 | Maravai LifeSciences Holdings Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001823239-26-000014 | CEO total compensation as printed in Maravai LifeSciences Holdings Inc.'s own proxy. As printed: 10,129,708. Filing ↗machine: t21 · r3 · c20 · span 502645–502655 |
| 56 | NeoGenomics, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001077183-26-000014 | CEO total compensation as printed in NeoGenomics, Inc.'s own proxy. As printed: 9,127,092. Filing ↗machine: r2 · c45 · span 869460–869469 |
| 57 | Guardant Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187403 | CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. Filing ↗machine: r7 · c31 · span 773149–773158 |
| 58 | Bio-Techne Corporation, Section 10b CEO total | DEF 14A | 2025-09-19 | 0001308179-25-000599 | CEO total compensation as printed in Bio-Techne Corporation's own proxy. As printed: 8,151,181. Filing ↗machine: span 792074–792083 |
| 59 | Tandem Diabetes Care, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001438133-26-000034 | CEO total compensation as printed in Tandem Diabetes Care, Inc.'s own proxy. As printed: 6,858,503. Filing ↗machine: r3 · c27 · span 866963–866972 |
| 60 | Certara, Inc., Section 10b CEO total | DEF 14A | 2026-04-03 | 0001104659-26-039372 | CEO total compensation as printed in Certara, Inc.'s own proxy. As printed: 6,491,387. Filing ↗machine: r1 · c42 · span 883232–883241 |
| 61 | 10x Genomics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001628280-26-027201 | CEO total compensation as printed in 10x Genomics, Inc.'s own proxy. As printed: 6,329,244. Filing ↗machine: r3 · c48 · span 583283–583292 |
| 62 | Repligen Corporation, Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-140115 | CEO total compensation as printed in Repligen Corporation's own proxy. As printed: 6,114,771. Filing ↗machine: t16 · r4 · c2 · span 577065–577074 |
| 63 | Myriad Genetics, Inc., Section 10b CEO total | DEF 14A | 2026-04-14 | 0000899923-26-000031 | CEO total compensation as printed in Myriad Genetics, Inc.'s own proxy. As printed: 5,686,740. Filing ↗machine: r2 · c24 · span 792987–792997 |
| 64 | Cryoport, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001140361-26-016129 | CEO total compensation as printed in Cryoport, Inc.'s own proxy. As printed: 2,375,524. Filing ↗machine: t277 · r2 · c22 · span 1285130–1285139 |
| 65 | Section 10a, Certara, Inc. reciprocity | DEF 14A | — | 0001104659-26-039372 | Certara, Inc.'s most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 66 | Section 10a, Natera, Inc. reciprocity | DEF 14A | — | 0001104659-26-047770 | Natera, Inc.'s most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 67 | Section 10a, Medpace Holdings, Inc. reciprocity | DEF 14A | — | 0001668397-26-000012 | Medpace Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 68 | Section 10a, Tandem Diabetes Care, Inc. reciprocity | DEF 14A | — | 0001438133-26-000034 | Tandem Diabetes Care, Inc.'s most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 69 | Section 10a, Haemonetics Corporation reciprocity | DEF 14A | — | 0000313143-26-000074 | Haemonetics Corporation names Azenta, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 70 | Section 10a, Guardant Health, Inc. reciprocity | DEF 14A | — | 0001193125-26-187403 | Guardant Health, Inc.'s most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 71 | Section 10a, Repligen Corporation reciprocity | DEF 14A | — | 0001193125-26-140115 | Repligen Corporation names Azenta, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 72 | Section 10a, 10x Genomics, Inc. reciprocity | DEF 14A | — | 0001628280-26-027201 | 10x Genomics, Inc. names Azenta, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 73 | Section 10a, Bio-Techne Corporation reciprocity | DEF 14A | — | 0001308179-25-000599 | Bio-Techne Corporation's most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 74 | Section 10a, NeoGenomics, Inc. reciprocity | DEF 14A | — | 0001077183-26-000014 | NeoGenomics, Inc.'s most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 75 | Section 10a, Maravai LifeSciences Holdings Inc. reciprocity | DEF 14A | — | 0001823239-26-000014 | Maravai LifeSciences Holdings Inc. names Azenta, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 76 | Section 10a, Sotera Health Company reciprocity | DEF 14A | — | 0001104659-26-040937 | Sotera Health Company's most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |